[go: up one dir, main page]

BR9509938A - Processo para aumentar a biodisponibilidade de um agente farmacéutico formulação farmacéutica para tratar um mamifero sofrendo de hipoesteroidismo osteoporose asma composição de substáncia - Google Patents

Processo para aumentar a biodisponibilidade de um agente farmacéutico formulação farmacéutica para tratar um mamifero sofrendo de hipoesteroidismo osteoporose asma composição de substáncia

Info

Publication number
BR9509938A
BR9509938A BR9509938A BR9509938A BR9509938A BR 9509938 A BR9509938 A BR 9509938A BR 9509938 A BR9509938 A BR 9509938A BR 9509938 A BR9509938 A BR 9509938A BR 9509938 A BR9509938 A BR 9509938A
Authority
BR
Brazil
Prior art keywords
steroidism
hypo
osteoporosis
bioavailability
asthma
Prior art date
Application number
BR9509938A
Other languages
English (en)
Inventor
Fred I Chasalow
Original Assignee
Amur Research Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amur Research Corp filed Critical Amur Research Corp
Publication of BR9509938A publication Critical patent/BR9509938A/pt

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/66Phosphorus compounds
    • A61K31/683Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols
    • A61K31/685Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols one of the hydroxy compounds having nitrogen atoms, e.g. phosphatidylserine, lecithin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52Purines, e.g. adenine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/557Eicosanoids, e.g. leukotrienes or prostaglandins
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/56Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/56Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/568Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/543Lipids, e.g. triglycerides; Polyamines, e.g. spermine or spermidine
    • A61K47/544Phospholipids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/08Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Rheumatology (AREA)
  • Biophysics (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
BR9509938A 1994-11-30 1995-11-09 Processo para aumentar a biodisponibilidade de um agente farmacéutico formulação farmacéutica para tratar um mamifero sofrendo de hipoesteroidismo osteoporose asma composição de substáncia BR9509938A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US34835594A 1994-11-30 1994-11-30
PCT/US1995/015100 WO1996016680A1 (en) 1994-11-30 1995-11-09 Phosphocholine drug derivatives

Publications (1)

Publication Number Publication Date
BR9509938A true BR9509938A (pt) 1998-01-27

Family

ID=23367654

Family Applications (1)

Application Number Title Priority Date Filing Date
BR9509938A BR9509938A (pt) 1994-11-30 1995-11-09 Processo para aumentar a biodisponibilidade de um agente farmacéutico formulação farmacéutica para tratar um mamifero sofrendo de hipoesteroidismo osteoporose asma composição de substáncia

Country Status (9)

Country Link
US (2) US5703063A (pt)
EP (1) EP0796112A4 (pt)
JP (1) JPH10509976A (pt)
AU (1) AU706267B2 (pt)
BR (1) BR9509938A (pt)
CA (1) CA2204902A1 (pt)
HU (1) HUT77514A (pt)
IL (1) IL115990A (pt)
WO (1) WO1996016680A1 (pt)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5660835A (en) * 1995-02-24 1997-08-26 East Carolina University Method of treating adenosine depletion
US20020032160A1 (en) * 1995-02-24 2002-03-14 Nyce Jonathan W. Compositions & formulations with an epiandrosterone or a ubiquinone & kits & their use for treatment of asthma symptoms & for reducing adenosine/adenosine receptor levels
GB9610122D0 (en) * 1996-05-15 1996-07-24 Reckitt & Colmann Prod Ltd Organic compositions
AU4892897A (en) * 1996-09-17 1998-04-14 Amur Pharmaceuticals, Inc. Phospholipid drug derivatives
JP2002536335A (ja) * 1999-02-03 2002-10-29 スーパージェン インコーポレイテッド ホスホコリン界面活性剤及びその使用
US7060290B1 (en) * 1999-02-18 2006-06-13 Supergen, Inc. Phosphocholine linked prodrug derivatives
US20050070487A1 (en) * 2001-04-24 2005-03-31 Nyce Jonathan W. Composition, formulations and kit for treatment of respiratory and lung disease with non-glucocorticoid steroids and/or ubiquinone and a bronchodilating agent
AU2002303427A1 (en) 2001-04-24 2002-11-05 East Carolina University Compositions and formulations with a non-glucocorticoid steroid and/or a ubiquinone and kit for treatment of respiratory and lung disease
AU2002366774A1 (en) * 2001-12-13 2003-07-09 So-Yeop Han A process for preparing n-acylated lysophosphatidylcholine and a pharmaceutical composition for treatment of metabolic bone disease comprising said compounds
ATE371680T1 (de) 2002-01-16 2007-09-15 Biocompatibles Uk Ltd Polymerkonjugate
CA2491846A1 (en) * 2002-06-17 2003-12-24 Epigenesis Pharmaceuticals Llc Dihydrate dehydroepiandrosterone and methods of treating asthma or chronic obstructive pulmonary disease using compositions thereof
US7405207B2 (en) 2002-06-17 2008-07-29 Epigenesis Pharmaceuticals, Inc. Nebulizer formulations of dehydroepiandrosterone and methods of treating asthma or chronic obstructive pulmonary disease using compositions thereof
GB0301014D0 (en) * 2003-01-16 2003-02-19 Biocompatibles Ltd Conjugation reactions
US20050026848A1 (en) * 2003-07-31 2005-02-03 Robinson Cynthia B. Combination of dehydroepiandrosterone or dehydroepiandrosterone-sulfate with a methylxanthine derivative for treatment of asthma or chronic obstructive pulmonary disease
US20050026881A1 (en) * 2003-07-31 2005-02-03 Robinson Cynthia B. Combination of dehydroepiandrosterone or dehydroepiandrosterone-sulfate with an anti-IgE antibody for treatment of asthma or chronic obstructive pulmonary disease
US20050101545A1 (en) * 2003-07-31 2005-05-12 Robinson Cynthia B. Combination of dehydroepiandrosterone or dehydroepiandrosterone-sulfate with an anticholinergic bronchodilator for treatment of asthma or chronic obstructive pulmonary disease
US20090263381A1 (en) * 2003-07-31 2009-10-22 Robinson Cynthia B Combination of dehydroepiandrosterone or dehydroepiandrosterone-sulfate with an anti-ige antibody for treatment of asthma or chronic obstructive pulmonary disease
US20050026884A1 (en) * 2003-07-31 2005-02-03 Robinson Cynthia B. Combination of dehydroepiandrosterone or dehydroepiandrosterone-sulfate with a beta-agonist bronchodilator for treatment of asthma or chronic obstructive pulmonary disease
US20090297611A1 (en) * 2003-07-31 2009-12-03 Robinson Cynthia B Combination of dehydroepiandrosterone or dehydroepiandrosterone-sulfate with a tyrosine kinase inhibitor, delta opioid receptor antagonist, neurokinin receptor antagonist, or vcam inhibitor for treatment of asthma or chronic obstructive pulmonary disease
US20050113318A1 (en) * 2003-07-31 2005-05-26 Robinson Cynthia B. Combination of dehydroepiandrosterone or dehydroepiandrosterone-sulfate with a beta-agonist bronchodilator for treatment of asthma or chronic obstructive pulmonary disease
US20110209699A1 (en) * 2003-07-31 2011-09-01 Robinson Cynthia B Combination of dehydroepiandrosterone or dehydroepiandrosterone-sulfate with a lipoxygenase inhibitor for treatment of asthma or chronic obstructive pulmonary disease
US20050026883A1 (en) * 2003-07-31 2005-02-03 Robinson Cynthia B. Combination of dehydroepiandrosterone or dehydroepiandrosterone-sulfate with a PDE-4 inhibitor for treatment of asthma or chronic obstructive pulmonary disease
US20050026879A1 (en) * 2003-07-31 2005-02-03 Robinson Cynthia B. Combination of dehydroepiandrosterone or dehydroepiandrosterone-sulfate with a tyrosine kinase inhibitor, delta opioid receptor antagonist, neurokinin receptor antagonist, or VCAM inhibitor for treatment of asthma or chronic obstructive pulmonary disease
US20090274676A1 (en) * 2003-07-31 2009-11-05 Robinson Cynthia B Combination of dehydroepiandrosterone or dehydroepiandrosterone-sulfate with a pde-4 inhibitor for treatment of asthma or chronic obstructive pulmonary disease
US20090285899A1 (en) * 2003-07-31 2009-11-19 Robinson Cynthia B Combination of dehydroepiandrosterone or dehydroepiandrosterone-sulfate with a methylxanthine derivative for treatment of asthma or chronic obstructive pulmonary disease
US20050026880A1 (en) * 2003-07-31 2005-02-03 Robinson Cynthia B. Combination of dehydroepiandrosterone or dehydroepiandrosterone-sulfate with a cromone for treatment of asthma or chronic obstructive pulmonary disease
US20050085430A1 (en) * 2003-07-31 2005-04-21 Robinson Cynthia B. Combination of dehydroepiandrosterone or dehydroepiandrosterone-sulfate with a PDE-4 inhibitor for treatment of asthma or chronic obstructive pulmonary disease
US20050043282A1 (en) * 2003-07-31 2005-02-24 Robinson Cynthia B. Combination of dehydroepiandrosterone or dehydroepiandrosterone-sulfate with a lipoxygenase inhibitor for treatment of asthma or chronic obstructive pulmonary disease
US20090285900A1 (en) * 2003-07-31 2009-11-19 Robinson Cynthia B Combination of dehydroepiandrosterone or dehydroepiandrosterone-sulfate with a beta-agonist bronchodilator for treatment of asthma or chronic obstructive pulmonary disease
US20050026882A1 (en) * 2003-07-31 2005-02-03 Robinson Cynthia B. Combination of dehydroepiandrosterone or dehydroepiandrosterone-sulfate with a leukotriene receptor antagonist for treatment of asthma or chronic obstructive pulmonary disease
US20050026890A1 (en) * 2003-07-31 2005-02-03 Robinson Cynthia B. Combination of dehydroepiandrosterone or dehydroepiandrosterone-sulfate with an antihistamine for treatment of asthma or chronic obstructive pulmonary disease
US20050038004A1 (en) * 2003-07-31 2005-02-17 Robinson Cynthia B. Combination of dehydroepiandrosterone or dehydroepiandrosterone-sulfate with an anticholinergic bronchodilator for treatment of asthma or chronic obstructive pulmonary disease
WO2005065954A1 (en) 2003-12-30 2005-07-21 Applera Corporation Apparatus and methods of depositing fluid
ES2629682T3 (es) 2004-03-29 2017-08-14 University Of South Florida Tratamiento efectivo de tumores y cáncer con fosfato de triciribina
WO2007071402A1 (en) * 2005-12-23 2007-06-28 Jado Technologies Gmbh Means and methods for the treatment and prevention of allergic diseases
US8703179B2 (en) * 2006-05-11 2014-04-22 Kimberly-Clark Worldwide, Inc. Mucosal formulation
JPWO2020116640A1 (ja) * 2018-12-07 2021-10-21 国立大学法人 東京大学 薬物複合体、ポリマー複合体及び薬物送達用組成物
CN120957729A (zh) * 2023-03-21 2025-11-14 R·萨曼特 新型磷酸酯化合物及其制备方法

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB487493A (en) * 1935-11-16 1938-06-21 Naamlooze Vennootschap Organon Production of biological preparations
EP0072936B1 (de) * 1981-08-12 1985-12-18 A. Nattermann & Cie. GmbH Neue O-alkyl-O-carbamoyl-glycero-phosphocholine und Verfahren zu ihrer Herstellung
CA1252778A (en) * 1983-08-25 1989-04-18 Hoffmann-La Roche Limited/Hoffmann-La Roche Limitee Steroids
US4891208A (en) * 1985-04-10 1990-01-02 The Liposome Company, Inc. Steroidal liposomes
US4897385A (en) * 1984-12-10 1990-01-30 American Cyanamid Company Antihypertensive phosphate derivatives
DE3445949A1 (de) * 1984-12-17 1986-06-19 A. Nattermann & Cie GmbH, 5000 Köln Verfahren zur isolierung eines begleitphospholipid-freien phosphatidylcholins
US4780455A (en) * 1985-04-12 1988-10-25 The Trustees Of Columbia University In The City Of New York Lipophilic complexes of pharmacologically active organic compounds
US4916249A (en) * 1985-07-03 1990-04-10 Hans Brachwitz Glycero-3(2)-phospho-L-serine derivatives and salts thereof
DE3827362A1 (de) * 1988-08-12 1990-02-15 Basf Ag Pulvrige, hydrophile theophyllinformulierung und verfahren zur ihrer herstellung
US5194654A (en) * 1989-11-22 1993-03-16 Vical, Inc. Lipid derivatives of phosphonoacids for liposomal incorporation and method of use
US5411947A (en) * 1989-06-28 1995-05-02 Vestar, Inc. Method of converting a drug to an orally available form by covalently bonding a lipid to the drug
WO1994008563A1 (en) * 1992-10-08 1994-04-28 Shaman Pharmaceutical, Inc. Novel class of phosphocholine derivatives having antifungal activity
US5529989A (en) * 1995-01-09 1996-06-25 Arizona Board Of Regents Acting On Behalf Of Arizona State University Pancratistatin prodrug

Also Published As

Publication number Publication date
EP0796112A1 (en) 1997-09-24
AU706267B2 (en) 1999-06-10
WO1996016680A1 (en) 1996-06-06
CA2204902A1 (en) 1996-06-06
US5703063A (en) 1997-12-30
AU4166196A (en) 1996-06-19
HUT77514A (hu) 1998-05-28
IL115990A0 (en) 1996-01-31
US5888990A (en) 1999-03-30
JPH10509976A (ja) 1998-09-29
IL115990A (en) 2002-11-10
EP0796112A4 (en) 1999-12-01

Similar Documents

Publication Publication Date Title
BR9509938A (pt) Processo para aumentar a biodisponibilidade de um agente farmacéutico formulação farmacéutica para tratar um mamifero sofrendo de hipoesteroidismo osteoporose asma composição de substáncia
BR9708014A (pt) Derivados de arilglicinamida processo para a preparação deles e composições farmacêuticas contendo estes compostos
BR9609780A (pt) Composto uso de um composto processo para o tratamento de condições composição farmacêutica processos para preparar uma composição farmacêutica e para preparar um composto
BR9503812A (pt) Composto composição farmacêutica utilização método de tratamento de um ser humano processo para a preparação de um composto
BR9611986A (pt) Compostos processo para a preparação dos mesmos composição farmcéutica e utilização dos compostos
BR9600821A (pt) Composto formulação farmacêutica e processo para a preparação de um composto
BR9407869A (pt) Combinaçao composiçao farmacêutica e processo para o tratamento de osteoporose
BR9602705A (pt) Composto composição farmacéutica processo para a preparação de um composto e uso
PT88612A (pt) Processo para a preparacao de composicoes farmaceuticas contendo um agente anti-calculo dental
BR9302737A (pt) Derivados de tiazolivinilfenila,processo para a preparacao de um composto,medicamento,uso e processos para tratar ou prevenir asma bronquica
BR9504509A (pt) Composto processo para sua preparaçao e formulaçao farmaceûtica
BR9604894A (pt) Derivado de acetamida processo para a preparação do mesmo e uma composição farmacêutica contendo o mesmo
PT93758A (pt) Processo para a preparacao de uma composicao de condicionamento de tecido que compreende complexos perfume/ciclodextrina
PT820276E (pt) Processo para a preparacao de particulas respiraveis
BR1100850A (pt) Composto, processo para a preparação de um composto, e, composição farmacêutica
BR9408148A (pt) Processo para tratamento de arritmia composto e formulação farmacêutica
BR9402126A (pt) Composição de monoéster de ácido do colofônio, composição, de boracha e processo para sua preparação
BR9505610A (pt) Composto composição farmacéutica processo para a preparação de um composto uso e método de tratar inflamação e dor
BR9602150A (pt) Compostos processo para sua preparação processo para a produção de uma formulação farmacêutica formulação farmacêutica e uso
BR9607346A (pt) Composto utilizaç o de um composto composiç o farmacéutica e processo para o tratamento de um mamifero e para e preparaç o de compostos
BR9502471A (pt) Composto de guanidina processo para preparar um composto de guanidina composição farmaceutica uso de um composto de guanidina método para o tratamento profilático ou terapêutico de doenças e processo para preparar uma composição farmacêutica
PT956054E (pt) Processo para vaporizar e sobeaquecer um agente de esterilizacao e dispositivo para a sua realizacao
PT900254E (pt) Processo para a preparacao de composicoes de betume
BR1100524A (pt) Compostos, processo para sua preparação; compostos intermediários para os mesmos, e composições farmacêuticas
PT1049721E (pt) Polissacaridos de sintese processo para a sua preparacao e composicoes farmaceuticas que os contem

Legal Events

Date Code Title Description
TC Change of name
PC Transfer

Free format text: SUPERGEN, INC (US)

B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B11B Dismissal acc. art. 36, par 1 of ipl - no reply within 90 days to fullfil the necessary requirements
B15K Others concerning applications: alteration of classification

Ipc: A61K 31/685 (2006.01), A61K 31/52 (2006.0